CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

ledipasvir, sofosbuvir

Last Updated: May 23, 2018
Result type: Reports
Project Number: SF0465-000
Product Line: Common Drug Review

Generic Name: ledipasvir, sofosbuvir

Brand Name: Harvoni

Manufacturer: Gilead Sciences Canada Inc.

Indications: Hepatitis C, chronic

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: May 18, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions